Healthcare has made over 1 trades of the ARCA biopharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Healthcare sold 1,541,331 units of ABIO stock worth 847,732$ on 26 February 2018.
The largest trade Healthcare's ever made was selling 1,541,331 units of ARCA biopharma Inc stock on 26 February 2018 worth over 847,732$. On average, Healthcare trades about 1,541,331 units every 0 days since 2018.
You can see the complete history of Healthcare Partners stock trades at the bottom of the page.
Over the last 16 years, insiders at ARCA biopharma Inc have traded over 9,048,465$ worth of ARCA biopharma Inc stock and bought 3,605,825 units worth 6,507,167$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of 636,994$. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth 17,047$.
arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.
ARCA biopharma Inc executives and other stock owners filed with the SEC include: